BrightPath Biotherapeutics Co., Ltd. (TYO:4594)
Japan · Delayed Price · Currency is JPY 45.00
+2.00 (4.65%)
Oct 9, 2026, 3:30 PM JST
TYO:4594 Revenue
In the fiscal year ending March 31, 2026, BrightPath Biotherapeutics had annual revenue of 84.00K JPY, down -92.59%. BrightPath Biotherapeutics had revenue of 51.00K in the quarter ending March 31, 2026, a decrease of -95.11%. That makes BrightPath Biotherapeutics the 47,684th largest company in the world by revenue and 3,881st in Japan.
Revenue
84.00K
Revenue Growth
-92.59%
P/S Ratio
74,406.01
Revenue / Employee
2.00K
Employees
42
Market Cap
6.25B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 84.00K | -1.05M | -92.59% |
| Mar 31, 2025 | 1.13M | 1.06M | 1,473.61% |
| Mar 31, 2024 | 72.00K | -353.93M | -99.98% |
| Mar 31, 2018 | 354.00M | -175.00M | -33.08% |
| Mar 31, 2017 | 529.00M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Soiken Holdings | 3.87B |
| CellSource | 3.67B |
| StemCell Institute | 2.81B |
| MEDINET | 998.00M |
| PRISM BioLab Co.,LTD | 737.27M |
| Carna Biosciences | 729.00M |
| SUSMED,Inc. | 497.00M |
| Cyfuse Biomedical K.K. | 305.00M |